Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital

Key Points

• D. Boral Capital reaffirmed a "buy" rating for Compass Therapeutics (CMPX) and set a target price of $32.00 for the stock.
• Compass Therapeutics' stock has seen a significant increase of 23.7%, with its market capitalization currently at $461.86 million.
• The company has an average analyst rating of "Buy" from nine analysts, with a consensus target price of $12.89, reflecting strong market confidence.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating reaffirmed by equities research analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $32.00 target price on the stock.

Several other equities analysts have also weighed in on CMPX. HC Wainwright reissued a "buy" rating and issued a $24.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 21st. Raymond James Financial raised shares of Compass Therapeutics to an "outperform" rating and set a $9.00 price objective on the stock in a research report on Tuesday, July 1st. Finally, Guggenheim increased their price objective on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Tuesday. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Compass Therapeutics currently has an average rating of "Buy" and a consensus target price of $12.89.

Compass Therapeutics Trading Up 23.7%

NASDAQ CMPX opened at $3.34 on Tuesday. The firm's fifty day moving average price is $2.74 and its two-hundred day moving average price is $2.49. Compass Therapeutics has a 1 year low of $1.12 and a 1 year high of $4.08. The firm has a market capitalization of $461.86 million, a P/E ratio of -8.15 and a beta of 1.49.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). On average, research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. MPM Bioimpact LLC boosted its stake in shares of Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after purchasing an additional 2,926,002 shares in the last quarter. Enavate Sciences GP LLC acquired a new stake in Compass Therapeutics during the 4th quarter worth approximately $11,293,000. Tang Capital Management LLC boosted its position in Compass Therapeutics by 225.4% during the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after buying an additional 4,087,005 shares during the period. Rock Springs Capital Management LP boosted its position in Compass Therapeutics by 2.7% during the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock worth $8,380,000 after buying an additional 150,336 shares during the period. Finally, Blue Owl Capital Holdings LP boosted its position in Compass Therapeutics by 2.6% during the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock worth $4,284,000 after buying an additional 75,000 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.